KB3305 is an investigational liver selective antagonist for the glucocorticoid receptor, developed by Karo Bio for the treatment of Type 2 Diabetes.
- Mechanism
- Curator reviewed
KB3305 is the first compound in a class of liver selective glucocorticoid antagonists. It inhibits the liver from increasing increase glucose production from the action of glucocorticoids, and may reduce the elevated hepatic glucose production in patients with type 2 diabetes, as well as risk factors including low density lipoprotein (LDL) cholesterols, triglycerides and free fatty acids in the plasma.
- Primary indication
- Investigated for use/treatment in diabetes mellitus type 2.Curator reviewed
- Formula / weight
- C54H75NO7 · 850.194 g/mol (avg)
- Also known as
- (4R)-4-((3S,5R,7R,8R,9S,10S,12S,13R,14S,17R)-7,12-DIHYDROXY-3-(2-(4-((8S,11R,13S,14S,17S)-17-HYDROXY-13-METHYL-3-OXO-17-PROP-1-YNYL-1,2,6,7,8,11,12,14,15,16-DECAHYDROCYCLOPENTA(A)PHENANTHREN-11-YL)-N-METHYL-ANILINO)ETHOXY)-10,13-DIMETHYL-2,3,4,5,6,7,8,9, · 3.BETA.,5.BETA.,7.ALPHA.,12.ALPHA.)-7,12-DIHYDROXY-3-(2-((4-((11.BETA.,17.BETA.)-17-HYDROXY-3-OXO-17-(1-PROPYN-1-YL)ESTRA-4,9-DIEN-11-YL)PHENYL)METHYLAMINO)ETHOXY)CHOLAN-24-OIC ACID · CHOLAN-24-OIC ACID, 7,12-DIHYDROXY-3-(2-((4-((11.BETA.,17.BETA.)-17-HYDROXY-3-OXO-17-(1-PROPYN-1-YL)ESTRA-4,9-DIEN-11-YL)PHENYL)METHYLAMINO)ETHOXY)-, (3.BETA.,5.BETA.,7.ALPHA.,12.ALPHA.)-
- Code names
- A-348441
Resolves to
LEUWECPXLBIBOF-LXEVTIFISA-NSMILES[H][C@@](C)(CCC(O)=O)[C@@]1([H])CC[C@@]2([H])[C@]3([H])[C@]([H])(O)C[C@]4([H])C[C@]([H])(CC[C@@]4(C)[C@@]3([H])C[C@]([H])(O)[C@@]12C)OCCN(C)C1=CC=C(C=C1)[C@@]1([H])C[C@]2(C)[C@@]([H])(CC[C@]2(O)C#CC)[C@]2([H])CCC3=CC(=O)CCC3=C12What you can answer from here — as of August 31, 2026
Which drugs share a target with KB3305, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account